Mach7 Company Update
Filed with ASX · · 4 pages · English
• Two successful expansion software license deals totalling at least $2.7 million • Additional contract wins pending and in final stages • EBITDA break-even target shifts to financial year ending 30 June 2018 (FY2018) • 3D Medical business being divested, expected cost savings of at least $1.2 million per annum • Annuity revenue stream & cash on hand alone conservatively valued at approximately $2
Mach7 Technologies Ltd. on 6ix
Earlier from Mach7 Technologies
- Resignation of Managing Director
- Appendix 4D and Half Yearly Report
- Mach7 on track to reach profitability in FY17
- Presentation to Shareholders at 2016 AGM
- Notice of Extraordinary General Meeting and Proxy Form
Later from Mach7 Technologies
- Prominent USA Radiology Group Selects Mach7
- Appointment of Chief Executive Officer
- FY2017 Appendix 4E and Financial Report
- Mach7 signs Agreement with Uni. of Vermont Medical Centre
- Appointment of Chief Executive Officer to the Board
Follow Mach7 Technologies into a list and get an email when it puts out news.
Follow Mach7 Technologies